TNFRSF17 and Miyoshi myopathy: Belantamab-mafodotin, the first-in-class antibody–drug conjugate consisting of an anti-BCMA mAb conjugated to a microtubule inhibitor monomethyl auristatin F, is approved for triple-refractory MM patients with a starting dose of 2.5 mg/kg adjusted based on drug-related toxicity, especially keratopathy.